WebAug 22, 2024 · BURLINGAME, Calif.--(BUSINESS WIRE)-- Innoviva Inc., (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of La Jolla Pharmaceutical … WebApr 12, 2024 · In other Innoviva news, CEO Pavel Raifeld purchased 3,000 shares of the company's stock in a transaction that occurred on Friday, March 10th. The stock was …
Innoviva Completes Acquisition of Entasis Therapeutics
WebApr 11, 2024 · In related news, CEO Pavel Raifeld bought 3,000 shares of Innoviva stock in a transaction that occurred on Friday, March 10th. The stock was acquired at an … WebCEO Pavel Raifeld. Forbes Lists #40. Best Small Cap Companies (2024) Dropped off in 2024. Drugs & Biotechnology. Innoviva (INVA) Stock Price Performance. Innoviva (INVA) Stock Key Data. cheri peters apex title
Innoviva Company Profile - Office Locations, Competitors ... - Craft
WebMar 1, 2024 · Pavel Raifeld, Chief Executive Officer Marianne Zhen, Chief Accounting Officer Operating Metrics View all Patents Issued 33 66.0% FY, 2016 Locations View all 2 location s detected Burlingame, CA HQ United States 1350 Old Bayshore Hwy #400 Brisbane, CA United States 2000 Sierra Point Pkwy #500 Report incorrect company … WebFeb 28, 2024 · Pavel Raifeld, Chief Executive Officer of Innoviva, stated: “Our diversified core royalty business remains solid. RELVAR ® /BREO ® ELLIPTA ® global net sales decreased in the fourth quarter... WebMay 23, 2024 · Innoviva to Acquire Entasis Therapeutics. Published: May 23, 2024. Innoviva to acquire all outstanding shares of Entasis it does not already own for $2.20 per share in cash. Price per share in cash represents a 50% premium to Entasis’ closing price of $1.47 per share on January 31, 2024, the last date before Innoviva’s original bid became ... cheri p.evans on facebook